Evidence map›Paper›PMID 23518928›Full record

Trial reportMolecular endocrinology (Baltimore, Md.)2013

TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression.

Mohan Liu, James N Ingle, Brooke L Fridley, Aman U Buzdar, Mark E Robson, Michiaki Kubo, Liewei Wang, Anthony Batzler, Gregory D Jenkins, Tracy L Pietrzak and 8 more

Open access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in Molecular endocrinology (Baltimore, Md.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Genetic Variation in Steroid and Xenobiotic Metabolizing Pathways and Enterolactone Excretion Before and After Flaxseed Intervention in African American and European American Women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019
    Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 2 countries.

Mohan LiuDivision of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA.
James N Ingle
Brooke L Fridley
Aman U Buzdar
Mark E Robson
Michiaki Kubo
Liewei Wang
Anthony Batzler
Gregory D Jenkins
Tracy L Pietrzak
Erin E Carlson
Matthew P Goetz
Donald W Northfelt
Edith A Perez
Clark V Williard
Daniel J Schaid
Yusuke Nakamura
Richard M Weinshilboum
Mayo Clinic · USMayo Clinic in Florida · USMayo Clinic in Arizona · USMemorial Sloan Kettering Cancer Center · USPrinceton University · USRIKEN Center for Integrative Medical Sciences · JPThe University of Texas MD Anderson Cancer Center · USUniversity of Chicago · US

Funding

Pharmacogenetics of Phase II Drug Metabolizing EnzymesU19GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2010 to 2014
$15.8M
INHERITED VARIATIONS IN DRUG-METABOLIZING ENZYMESR01GM028157 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 1985 to 2019
$6.9M
Tamoxifen biotransformation pathway pharmacogenomicsR01CA133049 · NCI · MAYO CLINIC ROCHESTER · PI GOETZ, MATTHEW PHILIP · 2008 to 2013
$2.3M
Pharmacogenomics of Breast Cancer Adjuvant ChemotherapyU01HG005137 · NHGRI · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2009 to 2011
$2.1M
Pharmacogenomics of cytosine arabinoside (Ara-C) and acute myelogenous leukemiaR01CA132780 · NCI · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2008 to 2013
$1.6M
Pharmacogenomics and Mechanisms of Cytidine AnaloguesR01CA138461 · NCI · MAYO CLINIC ROCHESTER · PI WANG, LIEWEI · 2009 to 2013
$1.5M
NCI NIH HHS P50 CA166201NCI NIH HHS R01 CA132780NCI NIH HHS R01 CA133049NCI NIH HHS R01 CA138461NHGRI NIH HHS U01 HG005137NIGMS NIH HHS R01 GM028157NIGMS NIH HHS R01 GM28157NIGMS NIH HHS U19 GM061388NIGMS NIH HHS U19 GM61388
6 · The paper itself

Abstract

We performed a discovery genome-wide association study to identify genetic factors associated with variation in plasma estradiol (E2) concentrations using DNA from 772 postmenopausal women with estrogen receptor (ER)-positive breast cancer prior to the initiation of aromatase inhibitor therapy. Association analyses showed that the single nucleotide polymorphisms (SNP) (rs1864729) with the lowest P value (P = 3.49E-08), mapped to chromosome 8 near TSPYL5. We also identified 17 imputed SNPs in or near TSPYL5 with P values < 5E-08, one of which, rs2583506, created a functional estrogen response element. We then used a panel of lymphoblastoid cell lines (LCLs) stably transfected with ERα with known genome-wide SNP genotypes to demonstrate that TSPYL5 expression increased after E2 exposure of cells heterozygous for variant TSPYL5 SNP genotypes, but not in those homozygous for wild-type alleles. TSPYL5 knockdown decreased, and overexpression increased aromatase (CYP19A1) expression in MCF-7 cells, LCLs, and adipocytes through the skin/adipose (I.4) promoter. Chromatin immunoprecipitation assay showed that TSPYL5 bound to the CYP19A1 I.4 promoter. A putative TSPYL5 binding motif was identified in 43 genes, and TSPYL5 appeared to function as a transcription factor for most of those genes. In summary, genome-wide significant SNPs in TSPYL5 were associated with elevated plasma E2 in postmenopausal breast cancer patients. SNP rs2583506 created a functional estrogen response element, and LCLs with variant SNP genotypes displayed increased E2-dependent TSPYL5 expression. TSPYL5 induced CYP19A1 expression and that of many other genes. These studies have revealed a novel mechanism for regulating aromatase expression and plasma E2 concentrations in postmenopausal women with ER(+) breast cancer.

Indexed as

Gene Expression Regulation, EnzymologicGenetic Association StudiesAgedAromataseBase SequenceBreast NeoplasmsChromatin ImmunoprecipitationChromosomes, Human, Pair 8EstradiolFemaleGene Expression Regulation, NeoplasticGenome-Wide Association StudyGenotypeHumansMCF-7 CellsMolecular Sequence DataAromataseEstradiolNuclear ProteinsRNA, MessengerTSPYL5 protein, human

Identifiers

PMID23518928
PMCPMC3607698
OpenAlexW2115156634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.